The value of economic modeling studies in the evaluation of treatment strategies for multiple sclerosis.
Detournay
Bruno
B
D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use; D000328:Adult; D002986:Clinical Trials as Topic; D017281:Cost of Illness; D003362:Cost-Benefit Analysis; D000068717:Glatiramer Acetate; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use; D016899:Interferon-beta / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use; D018803:Models, Economic; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000191:economics*; D010455:Peptides / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use; D013997:Time Factors
D000276:Adjuvants, Immunologic; D007166:Immunosuppressive Agents; D010455:Peptides; D000068717:Glatiramer Acetate; D016899:Interferon-beta